Login to Your Account

Cytokinetics Raising $33M For Clinic, Corporate Uses

By Jennifer Boggs

Thursday, January 19, 2006
Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription